147 related articles for article (PubMed ID: 27819670)
1. HSP110 promotes colorectal cancer growth through STAT3 activation.
Berthenet K; Bokhari A; Lagrange A; Marcion G; Boudesco C; Causse S; De Thonel A; Svrcek M; Goloudina AR; Dumont S; Hammann A; Biard DS; Demidov ON; Seigneuric R; Duval A; Collura A; Jego G; Garrido C
Oncogene; 2017 Apr; 36(16):2328-2336. PubMed ID: 27819670
[TBL] [Abstract][Full Text] [Related]
2. Extracellular HSP110 skews macrophage polarization in colorectal cancer.
Berthenet K; Boudesco C; Collura A; Svrcek M; Richaud S; Hammann A; Causse S; Yousfi N; Wanherdrick K; Duplomb L; Duval A; Garrido C; Jego G
Oncoimmunology; 2016 Jul; 5(7):e1170264. PubMed ID: 27622020
[TBL] [Abstract][Full Text] [Related]
3. Selecting the first chemical molecule inhibitor of HSP110 for colorectal cancer therapy.
Gozzi GJ; Gonzalez D; Boudesco C; Dias AMM; Gotthard G; Uyanik B; Dondaine L; Marcion G; Hermetet F; Denis C; Hardy L; Suzanne P; Douhard R; Jego G; Dubrez L; Demidov ON; Neiers F; Briand L; Sopková-de Oliveira Santos J; Voisin-Chiret AS; Garrido C
Cell Death Differ; 2020 Jan; 27(1):117-129. PubMed ID: 31068676
[TBL] [Abstract][Full Text] [Related]
4. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.
Collura A; Lagrange A; Svrcek M; Marisa L; Buhard O; Guilloux A; Wanherdrick K; Dorard C; Taieb A; Saget A; Loh M; Soong R; Zeps N; Platell C; Mews A; Iacopetta B; De Thonel A; Seigneuric R; Marcion G; Chapusot C; Lepage C; Bouvier AM; Gaub MP; Milano G; Selves J; Senet P; Delarue P; Arzouk H; Lacoste C; Coquelle A; Bengrine-Lefèvre L; Tournigand C; Lefèvre JH; Parc Y; Biard DS; Fléjou JF; Garrido C; Duval A
Gastroenterology; 2014 Feb; 146(2):401-11.e1. PubMed ID: 24512910
[TBL] [Abstract][Full Text] [Related]
5. Dominant high expression of wild-type HSP110 defines a poor prognostic subgroup of colorectal carcinomas with microsatellite instability: a whole-section immunohistochemical analysis.
Oh HJ; Kim JH; Lee TH; Park HE; Bae JM; Lee HS; Kang GH
APMIS; 2017 Dec; 125(12):1076-1083. PubMed ID: 28971530
[TBL] [Abstract][Full Text] [Related]
6. Consequences of the Hsp110DE9 mutation in tumorigenesis and the 5-fluorouracil-based chemotherapy response in Msh2-deficient mice.
Noel K; Bokhari A'; Bertrand R; Renaud F; Bourgoin P; Cohen R; Svrcek M; Joly AC; Duval A; Collura A
Cell Mol Life Sci; 2022 Jun; 79(6):332. PubMed ID: 35648235
[TBL] [Abstract][Full Text] [Related]
7. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.
Dorard C; de Thonel A; Collura A; Marisa L; Svrcek M; Lagrange A; Jego G; Wanherdrick K; Joly AL; Buhard O; Gobbo J; Penard-Lacronique V; Zouali H; Tubacher E; Kirzin S; Selves J; Milano G; Etienne-Grimaldi MC; Bengrine-Lefèvre L; Louvet C; Tournigand C; Lefèvre JH; Parc Y; Tiret E; Fléjou JF; Gaub MP; Garrido C; Duval A
Nat Med; 2011 Sep; 17(10):1283-9. PubMed ID: 21946539
[TBL] [Abstract][Full Text] [Related]
8. Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Kim KJ; Rhee YY; Oh S; Cho NY; Lee HS; Kang GH
Mod Pathol; 2014 Mar; 27(3):443-53. PubMed ID: 24030751
[TBL] [Abstract][Full Text] [Related]
9. Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model.
Zhuang Q; Hong F; Shen A; Zheng L; Zeng J; Lin W; Chen Y; Sferra TJ; Hong Z; Peng J
Int J Oncol; 2012 May; 40(5):1569-74. PubMed ID: 22218594
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
Zhang T; Jiang B; Zou ST; Liu F; Hua D
World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
[TBL] [Abstract][Full Text] [Related]
11. Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer.
Marcion G; Hermetet F; Neiers F; Uyanik B; Dondaine L; Dias AMM; Da Costa L; Moreau M; Bellaye PS; Collin B; Gobbo J; Briand L; Seigneuric R; Kitten O; Cinier M; Garrido C
Int J Cancer; 2021 Jun; 148(12):3019-3031. PubMed ID: 33506516
[TBL] [Abstract][Full Text] [Related]
12. HSP110 translocates to the nucleus upon genotoxic chemotherapy and promotes DNA repair in colorectal cancer cells.
Causse SZ; Marcion G; Chanteloup G; Uyanik B; Boudesco C; Grigorash BB; Douhard R; Dias AMM; Dumetier B; Dondaine L; Gozzi GJ; Moussay E; Paggetti J; Mirjolet C; de Thonel A; Dubrez L; Demidov ON; Gobbo J; Garrido C
Oncogene; 2019 Apr; 38(15):2767-2777. PubMed ID: 30542121
[TBL] [Abstract][Full Text] [Related]
13. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth.
Corvinus FM; Orth C; Moriggl R; Tsareva SA; Wagner S; Pfitzner EB; Baus D; Kaufmann R; Huber LA; Zatloukal K; Beug H; Ohlschläger P; Schütz A; Halbhuber KJ; Friedrich K
Neoplasia; 2005 Jun; 7(6):545-55. PubMed ID: 16036105
[TBL] [Abstract][Full Text] [Related]
14. Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer.
Kimura A; Ogata K; Altan B; Yokobori T; Ide M; Mochiki E; Toyomasu Y; Kogure N; Yanoma T; Suzuki M; Bai T; Oyama T; Kuwano H
Oncotarget; 2016 Apr; 7(14):18415-23. PubMed ID: 26943774
[TBL] [Abstract][Full Text] [Related]
15. Signal transducers and activators of transcription 3 activation is involved in nuclear accumulation of beta-catenin in colorectal cancer.
Kawada M; Seno H; Uenoyama Y; Sawabu T; Kanda N; Fukui H; Shimahara Y; Chiba T
Cancer Res; 2006 Mar; 66(6):2913-7. PubMed ID: 16540637
[TBL] [Abstract][Full Text] [Related]
16. microRNA-375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways.
Wei R; Yang Q; Han B; Li Y; Yao K; Yang X; Chen Z; Yang S; Zhou J; Li M; Yu H; Yu M; Cui Q
Oncotarget; 2017 Mar; 8(10):16633-16641. PubMed ID: 28186962
[TBL] [Abstract][Full Text] [Related]
17. Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis.
Kimura A; Ogata K; Altan B; Yokobori T; Mochiki E; Yanai M; Kogure N; Yanoma T; Suzuki M; Bai T; Kuwano H
World J Gastroenterol; 2017 Nov; 23(42):7541-7550. PubMed ID: 29204054
[TBL] [Abstract][Full Text] [Related]
18. BRG1 targeting STAT3/VEGFC signaling regulates lymphangiogenesis in colorectal cancer.
Zhu X; Sun L; Lan J; Xu L; Zhang M; Luo X; Gong J; Wang G; Yuan X; Hu J; Wang J
Oncotarget; 2016 Jun; 7(24):36501-36509. PubMed ID: 27145366
[TBL] [Abstract][Full Text] [Related]
19. Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis.
Chang YC; Su CY; Chen MH; Chen WS; Chen CL; Hsiao M
Mol Cancer; 2017 Aug; 16(1):135. PubMed ID: 28784136
[TBL] [Abstract][Full Text] [Related]
20. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Dobi E; Monnien F; Kim S; Ivanaj A; N'Guyen T; Demarchi M; Adotevi O; Thierry-Vuillemin A; Jary M; Kantelip B; Pivot X; Godet Y; Degano SV; Borg C
Clin Colorectal Cancer; 2013 Mar; 12(1):28-36. PubMed ID: 23083634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
